2025 年第 5 期 第 20 卷

海曲泊帕乙醇胺片对乳腺癌术后化疗所致血小板减少症的疗效观察

Observation on the effect of herombopag olamine tablet in the treatment of chemotherapy-induced thrombocytopenia after breast cancer surgery

作者：王超1张俊梅2张鹏1刘力1王晓春1

英文作者：Wang Chao1 Zhang Junmei2 Zhang Peng1 Liu Li1 Wang Xiaochun1

单位：1河北大学附属医院乳腺外科，保定071000；2河北省唐山市滦南县医院病理科，唐山063500

英文单位：1Department of Breast Surgery Affiliated Hospital of Hebei University Baoding 071000 China; 2Department of Pathology Luannan Hospital of Tangshan Hebei Province Tangshan 063500 China

关键词：血小板减少症；乳腺癌；海曲泊帕乙醇胺片

英文关键词：Thrombocytopenia;Breastcancer;Herombopagolaminetablet

• 摘要：

• 目的 探讨海曲泊帕乙醇胺片对乳腺癌术后化疗所致血小板减少症（CIT）的疗效。方法 选取在河北大学附属医院2021年12月至2023年12月确诊的乳腺癌术后化疗所致CIT患者120例，按照随机数字表法将患者分为重组人血小板生成素（rhTPO）组和联合组，各60例。rhTPO组采用rhTPO治疗，联合组在rhTPO基础上联合海曲泊帕乙醇胺片治疗，2组均连续治疗4周。比较2组患者治疗后的临床疗效、血小板参数、血小板生成素（TPO）、炎症因子、血小板计数（PLT）、免疫功能指标和不良反应发生情况。结果 联合组总有效率明显高于rhTPO组［91.7%(55/60)比75.0%(45/60)］，差异有统计学意义（P=0.014）。治疗后，2组患者血小板体积分布宽度、平均血小板体积均低于治疗前，且联合组低于rhTPO组，血小板压积均高于治疗前，且联合组高于rhTPO组（均P＜0.05）。治疗后，2组患者白细胞介素6、TPO和肿瘤坏死因子α均低于治疗前，且联合组显著低于rhTPO组（均P＜0.05）。治疗第3、7、14天，2组患者的PLT水平均高于治疗前，且联合组均高于rhTPO组（均P＜0.05）。与治疗前相比，2组患者治疗后的CD+3、CD+4水平和CD+4/CD+8比值均显著提高，且联合组均高于rhTPO组（均P＜0.05）。治疗后，2组不良反应发生率比较，差异无统计学意义（P=0.488）。结论 海曲泊帕乙醇胺片联合rhTPO治疗乳腺癌术后化疗所致CIT，可以提高临床疗效，降低患者血清白细胞介素6、TPO和肿瘤坏死因子α水平，提高PLT和免疫功能，具有较高的安全性。

• Objective To investigate the efficacy of herombopag olamine tablet in the treatment of chemotherapy-induced thrombocytopenia (CIT) after breast cancer surgery.Methods A total of 120 patients with CIT caused by chemotherapy after breast cancer surgery diagnosed in Affiliated Hospital of Hebei University from December 2021 to December 2023 were selected. According to the random number table method, the patients were divided into recombinant human thrombopoietin (rhTPO) group and combined group, with 60 cases in each group. The rhTPO group was treated with rhTPO, and the combination group was treated with rhTPO and herombopag olamine tablets. Both groups were treated for 4 weeks. The clinical efficacy, platelet parameters, thrombopoietin (TPO), inflammatory factors, platelet count (PLT), immune function indexes and adverse reactions were compared between the two groups after treatment. Results The total effective rate in the combined group was significantly higher than that in the rhTPO group ［91.7%(55/60) vs 75.0%(45/60)］(P= 0.014). After treatment, the platelet volume distribution width and mean platelet volume in the two groups were lower than those before treatment, and those in the combined group were lower than those in the rhTPO group, and the platelet crit was higher than that before treatment, and those in the combined group were higher than those in the rhTPO group （all P＜0.05）. After treatment, the levels of IL-6, TPO and tumor necrosis factor-α in the two groups were lower than those before treatment, and those in the combined group were significantly lower than those in the rhTPO group (all P＜0.05). After 3, 7 and 14 days of treatment, the PLT levels of the two groups were higher than those before treatment, and the PLT levels of the combined group were higher than those of the rhTPO group (all P＜0.05). Compared with before treatment, the levels of CD+3, CD+4, and CD+4/CD+8 ratio in the two groups after treatment were significantly increased, and those in the combined group were higher than those in the rhTPO group (all P＜0.05). After treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P=0.488). Conclusion Herombopag olamine tablet combined with rhTPO in the treatment of CIT caused by chemotherapy after breast cancer surgery can improve the clinical efficacy of patients, reduce the levels of serum interleukin-6, TPO and tumor necrosis factor-α, improve PLT and immune function, and has high safety.